ACAD ACADIA Pharmaceuticals Inc.

29.61
+0.59  (+2%)
Previous Close 29.02
Open 29.32
Price To Book 11.01
Market Cap 4,278,272,743
Shares 144,487,428
Volume 1,102,958
Short Ratio
Av. Daily Volume 1,401,575

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiation announced April 25, 2019.
Pimavanserin - CLARITY-2
Adjunctive Treatment in Patients With Major Depressive Disorder
Phase 2 data due year-end 2019.
Pimavanserin - Advance
Adjunctive treatment in patients with negative symptoms of schizophrenia
Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - Enhance
Adjunctive treatment of schizophrenia
Announced October 4, 2017 that trial will be discontinued.
Pimavanserin - SERENE
Alzheimer’s disease agitation
Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin
Parkinson’s disease psychosis (PDP)
Phase 3 interim data 2H 2019 with final data due 2020.
Pimavanserin - Harmony
Alzheimer’s disease psychosis
Phase 3 trial to be initiated 4Q 2019.
Trofinetide
Rett Syndrome

Latest News

  1. Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
  2. Top Ranked Momentum Stocks to Buy for August 15th
  3. ACADIA Pharmaceuticals Inc. (ACAD) Shares March Higher, Can It Continue?
  4. Edited Transcript of ACAD earnings conference call or presentation 31-Jul-19 8:30pm GMT
  5. Why Acadia Pharmaceuticals Stock Is Crushing It Today
  6. Acadia Pharmaceuticals Beats Expectations in Q2
  7. Acadia Pharmaceuticals (ACAD) Q2 2019 Earnings Call Transcript
  8. Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
  9. ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results
  10. ACADIA Pharmaceuticals, Inc. to Host Earnings Call
  11. The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster
  12. Will Acadia Pharmaceuticals (ACAD) Report Negative Earnings Next Week? What You Should Know
  13. Why Acadia Pharmaceuticals Is Tanking Today
  14. Are These 2 Beaten-Down Biotech Stocks Worth Buying?
  15. Why Is Acadia Pharmaceuticals Falling Today?
  16. The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
  17. Acadia stock drops as schizophrenia drug doesn't pass clinical trial
  18. Acadia's schizophrenia treatment misses late-stage main goal; shares fall 16%
  19. Acadia's schizophrenia treatment fails to meet main goal of late-stage study
  20. ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia